Daily Roundup | uniQure's Mixed Huntington's Readout & AstraZeneca's $2B Summit Deal

September 29 edition: uniQure's four-year Huntington's readout is mixed, while its filing rests on earlier data. AstraZeneca agrees to invest $2 billion in Summit alongside a cancer-combination program, without acquiring Summit's drug rights. In the roundup: Veracyte's retrospective Decipher analysis in prostate cancer; FDA approval of Teva's Xgeva biosimilar; and Novo's license to Hengrui's early oral GLP-1/GIP program. Invivyd reports tolerability, not protection, results for VYD2311, and we examine the September 29 implementation of Section 232 drug tariffs.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.